SAB Biotherapeutics Inc (SABSW) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.03
• P/E Ratio: 0.13
• EPS: $0.29
• 52-Week High: $0.06
• 52-Week Low: $0.02

About SAB Biotherapeutics Inc

SAB Biotherapeutics, Inc. is an innovative biopharmaceutical company focused on developing advanced immunotherapies aimed at treating infectious diseases, autoimmune disorders, and various forms of cancer. With a strong operational base in Sioux Falls, South Dakota, and a strategic presence in Cambridge, Massachusetts, SAB leverages its proprietary technology to harness the power of immunoglobulin to produce therapeutic antibodies. The company's robust pipeline reflects its commitment to addr...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for SAB Biotherapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does SABSW pay dividends?

SAB Biotherapeutics Inc (SABSW) does not currently pay a regular dividend.

What is SABSW's P/E ratio?

SAB Biotherapeutics Inc has a price-to-earnings (P/E) ratio of 0.13.